5 Best Large Cap Dividend Growth Stocks to Invest In

4. McKesson Corporation (NYSE:MCK)

Number of Hedge Fund Holders: 72

On April 28, William Blair initiated coverage of McKesson Corporation (NYSE:MCK) with an Outperform rating. The company has a “durable competitive moat” with specialty-led growth upside, the analyst tells investors in a research note. The firm believes McKesson is well-positioned to benefit from a favorable demand backdrop, supported by demographic trends and rising use of specialty medicines.

On April 20, Reuters reported that McKesson will sell a minority stake in its medical-surgical solutions business to Apollo Global Management for $1.25 billion, as the company plans to spin off the unit through an initial public offering. Apollo will acquire about 13% of the business through a convertible preferred equity investment, valuing it at roughly $13 billion, while McKesson will retain control and majority ownership of the unit, the companies said.McKesson is streamlining its operations to focus on its core pharmaceutical distribution business after years of investor pressure.

The investment by Apollo is a crucial milestone that helps reduce uncertainty around the medical-surgical unit’s standalone valuation, Leerink Partners analyst Michael Cherny said. The company first outlined plans to spin off the unit in May 2025. Since then, it has exited several overseas markets and divested other non-core assets over the past few years.

McKesson Corporation (NYSE:MCK) is a diversified healthcare services company focused on improving patient outcomes. Its US Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter drugs, along with other healthcare-related products across the United States.